FDA OKs BioCryst Orladeyo to prevent attacks in hereditary angioedema

• The FDA has appoved BioCryst Pharmaceuticals' (NASDAQ:BCRX) oral, once-daily Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
• HAE is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway.
• https://seekingalpha.com/news/3641613-fda-oks-biocryst-pharmas-orladeyo-to-prevent-attacks-in-hereditary-angioedema